SOURCE-LINKED STUDY SUMMARY
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Sponsor announcement summarizedQuality not appraised
- What was studied
- Preliminary sponsor results compared eloralintide plus tirzepatide with individual treatments and placebo.
- Who / model studied
- 367 adults with overweight/obesity and type 2 diabetes in a randomized, double-blind trial.
- Studied dose & schedule
- Separate injections over 48 weeks; the reported top combination targeted eloralintide 9 mg plus tirzepatide 15 mg. Frequency was not verified for this card.
- What the study found
- Efficacy-estimand weight change: -23.3 percent for that combination, -14.8 percent for tirzepatide and -3.0 percent for placebo. Adverse-event discontinuations across combination arms: 10.8–27.0%, versus 2.9% with tirzepatide.
- Limitations & context
- Sponsor disclosure, not a peer-reviewed full report. Combination-versus-placebo was primary; active comparisons were secondary. Missing confidence intervals and alternative estimands limit interpretation. GI events were more frequent with combinations.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: sponsor announcement, full poster not reviewed. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.